Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences.
| SAN FRANCISCO, May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences:
The presentations will be accessible via webcast through links posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. The webcasts will be available for replay until July 6, 2024 and July 10, 2024, respectively. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn. Contact: For Investors: For Media:
SOURCE Nektar Therapeutics | ||
Company Codes: NASDAQ-NMS:NKTR |
View original content to download multimedia:
